Pharmacological characterization of F-180:: a selective human V1a vasopressin receptor agonist of high affinity

被引:25
作者
Andrés, M
Trueba, M
Guillon, G [1 ]
机构
[1] INSERM, U469, 141 Rue Cardonille, F-34094 Montpellier 05, France
[2] Univ Basque Country, Fac Sci, Dept Biochem & Mol Biol, E-48080 Bilbao, Spain
关键词
F-180; vasopressin; agonist; V-1a receptors;
D O I
10.1038/sj.bjp.0704634
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The pharmacological properties of F-180, a vasopressin (VP) structural analogue, were determined on CHO cells expressing the different human vasopressin and oxytocin (OT) receptor subtypes. Binding experiments revealed that F-180 exhibited a high affinity for the human Via receptor subtype (K-i = 11 nM) and was selective for this receptor subtype. 2 Functional studies performed on CHO cells expressing human Via receptors indicate that similarly to AVP, F-180 can stimulate the accumulation of inositol phosphate. The activation constant (K-act) for both F-180 and AVP was 1.7 nm. F-180 was also an agonist for the human V-2 and V-1b receptor subtypes and an antagonist for the human OT receptor. 3 Since marked species pharmacological differences for vasopressin receptors have been described, we studied the properties of F-180 on various mammalian species. F-180 showed high affinity and good selectivity for human and bovine Via receptors, but weak affinity and non selective properties for rat Via receptors. 4 To assess the functional properties of F-180 on a native biological model, we performed studies on primary cultures of cells from bovine zona fasciculata (ZF). As AVP, F-180 stimulated inositol phosphate accumulation and cortisol secretion with similar efficiency. 5 In conclusion, we demonstrate that F-180 is the first selective Via agonist described for human and bovine vasopressin receptors. Therefore F-180 can be used as a powerful pharmacological tool to characterize the actions of vasopressin that are mediated by Via receptor subtypes. British Journal of Pharmacology.
引用
收藏
页码:1828 / 1836
页数:9
相关论文
共 35 条
[21]   CLONING AND CHARACTERIZATION OF A VASOPRESSIN V2 RECEPTOR AND POSSIBLE LINK TO NEPHROGENIC DIABETES-INSIPIDUS [J].
LOLAIT, SJ ;
OCARROLL, AM ;
MCBRIDE, OW ;
KONIG, M ;
MOREL, A ;
BROWNSTEIN, MJ .
NATURE, 1992, 357 (6376) :336-339
[22]   A SIMPLE AND RAPID METHOD FOR THE PREPARATION OF PLASMA-MEMBRANES [J].
MAEDA, T ;
BALAKRISHNAN, K ;
MEHDI, SQ .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 731 (01) :115-120
[23]   MOLECULAR-CLONING AND EXPRESSION OF A RAT VIA ARGININE VASOPRESSIN RECEPTOR [J].
MOREL, A ;
OCARROLL, AM ;
BROWNSTEIN, MJ ;
LOLAIT, SJ .
NATURE, 1992, 356 (6369) :523-526
[24]  
Nakamura S, 1998, N-S ARCH PHARMACOL, V358, pR551
[25]   RADIOLIGAND BINDING-STUDIES REVEAL MARKED SPECIES-DIFFERENCES IN THE VASOPRESSIN-V(1) RECEPTOR OF RAT, RHESUS AND HUMAN TISSUES [J].
PETTIBONE, DJ ;
KISHEL, MT ;
WOYDEN, CJ ;
CLINESCHMIDT, BV ;
BOCK, MG ;
FREIDINGER, RM ;
VEBER, DF ;
WILLIAMS, PD .
LIFE SCIENCES, 1992, 50 (25) :1953-1958
[26]   1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V-1b vasopressin receptor [J].
Saito, M ;
Tahara, A ;
Sugimoto, T .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) :1711-1717
[27]   A POTENT NEW SYNTHETIC ANALOG OF VASOPRESSIN WITH RELATIVE AGONIST SPECIFICITY FOR THE PITUITARY [J].
SCHWARTZ, J ;
DERDOWSKA, I ;
SOBOCINSKA, M ;
KUPRYSZEWSKI, G .
ENDOCRINOLOGY, 1991, 129 (02) :1107-1109
[28]   BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF SR-49059, A NEW, POTENT, NONPEPTIDE ANTAGONIST OF RAT AND HUMAN VASOPRESSIN V1A RECEPTORS [J].
SERRADEILLEGAL, C ;
WAGNON, J ;
GARCIA, C ;
LACOUR, C ;
GUIRAUDOU, P ;
CHRISTOPHE, B ;
VILLANOVA, G ;
NISATO, D ;
MAFFRAND, JP ;
LEFUR, G ;
GUILLON, G ;
CANTAU, B ;
BARBERIS, C ;
TRUEBA, M ;
ALA, Y ;
JARD, S .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :224-231
[29]   Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V-2 receptor antagonist [J].
SerradeilLeGal, C ;
Lacour, C ;
Valette, G ;
Garcia, G ;
Foulon, L ;
Galindo, G ;
Bankir, L ;
Pouzet, B ;
Guillon, G ;
Barberis, C ;
Chicot, D ;
Jard, S ;
Vilain, P ;
Garcia, C ;
Marty, E ;
Raufaste, D ;
Brossard, G ;
Nisato, D ;
Maffrand, JP ;
LeFur, G .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12) :2729-2738
[30]  
SERRADEILLEGAL C, 2001, WORLD C NEUR HORM BO, P40